Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00582907|
Recruitment Status : Completed
First Posted : December 28, 2007
Results First Posted : October 31, 2012
Last Update Posted : February 11, 2013
Familial Mediterranean fever (FMF) is a genetic disease resulting in recurrent attacks of fever, abdominal pain, chest pain, arthritis and rash. There are 5-15% of patients who continue to have FMF attacks despite treatment with colchicine or who cannot tolerate colchicine. Currently there are no alternatives to colchicine. Pyrin, the protein that has a defect in FMF has an important role in the regulation of a molecule called interleukin (IL)-1 beta production and activity. This molecule is very important in the process of inflammation in FMF.
Therefore we propose to use IL-1 Trap (Rilonacept), a medication that binds and neutralizes IL-1.
We will enroll in this study 17 subjects from the age of 4 years, including adults with active FMF despite colchicine therapy. Subjects will receive in random order two 3-month courses of Rilonacept at 2.2 mg/kg (maximum 160 mg) by weekly subcutaneous injection and two 3-month courses of placebo injection. If patients have at least two FMF attacks during a treatment course they will be able to get if they choose the other treatment until the end of that treatment course. Our hypothesis is that Rilonacept will decrease the number of acute FMF attacks and will be safe to use. This study may confirm the importance of IL-1 in the cause of FMF.
Funding source - FDA Office of Orphan Products Development
|Condition or disease||Intervention/treatment||Phase|
|Familial Mediterranean Fever||Drug: Rilonacept Drug: Placebo||Phase 2|
Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory genetic disorder resulting in recurrent attacks of fever, serositis, arthritis and rash. Late complications of untreated FMF include the development of renal amyloidosis. FMF is a rare orphan disease in the United States. Treatment with colchicine is effective in reducing the frequency of episodes in most patients and the development of amyloidosis in nearly all patients. However, there are still 5-15% of patients who continue to have acute FMF attacks despite colchicine therapy or are intolerant of colchicine, usually from gastrointestinal adverse effects. Currently there are no effective alternatives to colchicine. Pyrin, the mutated protein in FMF has an important role in the regulation of IL-1 beta production and activity. Mutations in pyrin result in increased IL-1 beta levels in mice and humans. IL-1 beta is an important pro-inflammatory cytokine. Thus, we hypothesize that inhibition of IL-1 will decrease acute attacks in patients with FMF. We propose to use IL-1 Trap (Rilonacept), a fusion protein consisting of human IL-1 cytokine receptor extracellular domains and the FC portion of human IgG1 that binds and neutralizes IL-1.
We will enroll 17 subjects from the age of 4 years, including adults, from multiple centers in the United States with active FMF (at least 1 attack per month) despite receiving at least 1.2-1.5 mg/d of colchicine (dose dependent on age) or are intolerant of colchicine. Subjects will be diagnosed by clinical criteria with at least one heterozygote mutation of the MEFV (pyrin) gene. After screening subjects will be monitored for a month to observe for acute FMF attacks or if they did not develop an attack in that month until they develop two attacks. We will then use a single-subject alternating treatments design with subjects receiving in random order two 3-month courses of Rilonacept at 2.2 mg/kg (max 160 mg) by weekly SC injection and two 3-month courses of comparable volume placebo. Subjects will continue the usual colchicine dose they were on when they started the study. Subjects with 2 acute FMF attacks during a treatment course will be able to crossover to the other treatment arm until the end of that treatment course. There will be 10 study visits: 1. Screening. 2. Treatment baseline after one month or after subjects have developed FMF attacks as described above. After 1 month of each treatment course and at the end of each treatment course (overall 8 visits). At each visit subjects will return completed diary forms, used and unused drug, queried on adverse effects, undergo a physical examination and laboratory tests obtained for inflammation, safety and in some visits for translational studies. Subjects will also fill out quality of life questionnaires and give an overall estimation of the disease activity. Results will be analyzed by traditional frequency statistics (using an intent to treat analysis) and by Bayesian hierarchical modeling. Our primary aim is to assess the efficacy of Rilonacept in decreasing the number of acute FMF attacks while monitoring drug safety.
The significance of the study includes short and long-term benefits. Fewer FMF attacks will result in less functional impairment and a higher quality of life in colchicine resistant or intolerant patients. Once weekly injections have the potential to improve treatment compliance. Fewer acute attacks of arthritis may prevent the development of chronic joint damage. In the long-term, better FMF control may prevent amyloidosis. This study may confirm the importance of IL-1 in the pathogenesis of FMF and provide support for an FDA filing for use of Rilonacept in FMF. The study design may serve as a template for trials of new biologic drugs for rare diseases.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF)|
|Study Start Date :||August 2008|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||September 2011|
U.S. FDA Resources
Treatment Arm A: Rilonacept (IL-1 Trap) at a dose of 2.2 mg/kg/wk (max 160 mg)given by subcutaneous injection for 3 months plus colchicine at a stable dose for those subjects already taking colchicine, or without colchicine for those intolerant or non-compliant with colchicine. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention
2.2 mg/kg/wk by subcutaneous injection, for 3 months
Other Name: Arcalyst, IL-1 Trap
Placebo Comparator: 2
Treatment Arm B: Placebo given by subcutaneous injection weekly with or without colchicine for 3 months. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention.
placebo by subcutaneous injection weekly for 3 months
- To Assess the Efficacy of Rilonacept in Decreasing the Number of Acute FMF Attacks. [ Time Frame: attacks were assessed at the end of each 3 month treatment course (overall up to 6 month of rilonacept and 6 months of placebo, each) ]Difference in number of attacks per treatment month between rilonacept and placebo
- To Determine if There is a Medically Important Difference Between the Safety Profiles of Rilonacept vs. Placebo. [ Time Frame: 12 months of entire study length ]Differences in adverse events (AEs) between rilonacept and placebo per patient-month of treatment. We separately analyzed injection site reactions and infectious adverse events. Other adverse events were too small in number to analyze. The upper table (and first statistical analysis) regards injection site reactions and lower table (and second statistical analysis) regards infections.
- To Determine the Difference in the Length of Attacks During Treatment With Rilonacept vs. Placebo. [ Time Frame: 12 months ]This outcome was the difference in days in the length of attacks between rilonacept and placebo.
- Percentage of Treatment Courses Without FMF Attacks in Rilonacept Courses as Compared to Placebo Courses. [ Time Frame: Each treatment course of up to 3 months ]The percentage of rilonacept and placebo treatment courses without FMF attacks.
- To Determine the Proportion of Courses in Which Subjects Attained at Least a 50% Decrease in Acute FMF Attacks During Rilonacept Courses as Compared to Placebo Courses. [ Time Frame: Up to 3 months for each treatment course ]Differences between rilonacept and placebo in the percentage of courses that attained at least a 50% decrease in FMF attacks when compared to attacks in the screening period.
- To Determine Differences in the Time to the Development of Attacks Between the Treatment Arms (Rilonacept vs. Placebo). [ Time Frame: 3 months ]In a survival analysis we measured the difference (in days) until the development of the first and second attack within a treatment course of up to 3 months and examined differences in this parameter between rilonacept and placebo. Data regarding the development of the second attack are reported below. In regards to the first attack there were no significant differences between rilonacept and placebo (20 days (7.5,>90)for rilonacept; 15 (8,32) for placebo, P=0.066).
- To Determine the Differences in the Erythrocyte Sedimentation Rate Between the Treatment Arms (Rilonacept vs. Placebo). [ Time Frame: 3 months (each treatment course, overall 12 months) ]Erythrocyte sedimentation rate - ESR (mm/h)
- To Determine the Differences in C-Reactive Protein Between the Treatment Arms (Rilonacept vs. Placebo) [ Time Frame: 3 months (each treatment course, overall 12 months) ]Differences between the treatment courses in the C-Reactive Protein levels mg/L
- To Determine the Differences in the Platelet Count Between the Treatment Arms (Rilonacept vs. Placebo) [ Time Frame: 3 months (each treatment course, overall 12 months) ]The difference between the treatment arms in the platelet count X 10 to the power of 9
- To Determine the Differences in the Fibrinogen Levels Between the Treatment Arms (Rilonacept vs. Placebo) [ Time Frame: 3 months (each treatment course, overall 12 months) ]The differences between treatment arms in the fibrinogen level (micromol/L)
- To Determine the Differences in Serum Amyloid A Levels Between the Treatment Arms (Rilonacept vs. Placebo) [ Time Frame: 3 months (each treatment course, overall 12 months) ]The difference between the treatment arms in serum amyloid A levels (mg/L)
- To Determine the Differences in the Quality of Life Between the Treatment Arms (Rilonacept vs. Placebo). [ Time Frame: 12 months ]Differences in the health-related quality of life (HRQOL) during treatment with rilonacept vs. placebo. HRQOl was measured by the Childhood Health Questionnaire which was adopted also for adults. There are 2 summary scores: 1. Physical summary score. 2. Psychosocial summary score. The data reported below in the upper table is the physical summary composite score and in the lower table the psychosocial summary composite score. Scores were from 0-100 (higher is better) with a score of 50 representing the mean of the normal population.
- To Determine the Differences in the FMF Severity Score of the Subjects Between the Treatment Arms (Rilonacept vs. Placebo). [ Time Frame: overall 12 months ]Differences in the Armenian Evaluation Score between rilonacept and placebo courses. The Armenian Evaluation Score is a composite score of disease severity based on the frequency, duration and character of attacks (degree of fever and severity of serositis). It was adapted to calculate a score for a 3-month treatment course. The lowest (best) score is 0 and higher values are worse. In theory there is no upper limit to the scale. The total score is reported (there are no subscales).
- To Determine the Differences in the Proportion of Time Subjects Received Rilonacept vs Placebo [ Time Frame: 12 months ]The proportion of time within the trial that participants received rilonacept as opposed to placebo. The reason for this outcome is that participants who had at least 2 attacks within an individual treatment course were able to "escape" in a blinded manner to the other treatment arm until the end of that treatment course and then resume the original randomization sequence. Thus participants may have been treated for a longer time with one treatment arm or the other.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00582907
|United States, California|
|Children's Hospital Los Angeles/Cedars-Sinai Medical Center|
|Los Angeles, California, United States, 90027|
|Children's Hospital of Central California|
|Madera, California, United States, 93638|
|United States, Maryland|
|Bethesda, Maryland, United States, 20892|
|United States, New York|
|NYU Hospital for Joint Diseases|
|New York, New York, United States, 10003|
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Study Director:||Philip J Hashkes, MD, MSc||Shaare Zedek Medical Center/The Cleveland Clinic Foundation|